Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
• People: making a positive impact on health and society and greater diversity in our sector helps people thrive.
• Planet: contributing to tackling climate change and resource scarcity helps our planet thrive.
• Foundation: the processes, priorities and the relationships we’re building across the value chain that will help shape a resilient company.
In an age of crisis, can the biopharma industry withstand global shocks?
As the world navigates the greatest public health crisis in recent memory, the biopharma industry has taken a leading role in fighting COVID-19. How can we measure our ability to deliver on not only this challenge, but others that are to come?
In collaboration with Longitude, a Financial Times company, Cytiva has developed the Global Biopharma Resilience Index. This index uses survey response data to rank biopharma capabilities and resilience in 20 countries, scoring each on five factors critical to meeting global demand during a public health crisis:
Build your skills and continue your education with our eLearning courses.